Biomea Fusion News

Biomea Fusion Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Biomea Fusion Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow JonesMay 4 03:59

HC Wainwright & Co. : Biomea Fusion (BMEA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.

HC Wainwright & Co. : Biomea Fusion (BMEA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.

Zhitong FinanceMay 4 03:50

HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $50 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $50 price target.

BenzingaMay 4 03:49

Biomea Fusion Is Maintained at Neutral by JP Morgan

Biomea Fusion Is Maintained at Neutral by JP Morgan

Dow JonesMay 3 23:32

JP Morgan Maintains Neutral on Biomea Fusion, Raises Price Target to $15

JP Morgan analyst Eric Joseph maintains Biomea Fusion with a Neutral and raises the price target from $14 to $15.

Analyst UpgradesMay 3 23:22

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)

TipRanksMay 3 19:42

Barclays Sticks to Its Buy Rating for Biomea Fusion (BMEA)

TipRanksMay 3 18:41

Biomea Fusion GAAP EPS of -$1.09 Misses by $0.02

Seeking AlphaMay 3 13:50

Biomea Fusion (BMEA.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -1.09 dollars, previous value of -0.98 dollars, and expected value of -0.99 dollars.

Biomea Fusion (BMEA.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -1.09 dollars, previous value of -0.98 dollars, and expected value of -0.99 dollars.

Zhitong FinanceMay 3 07:00

Biomea Fusion Q1 EPS $(1.09) Misses $(0.91) Estimate

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.91) by 19.78 percent. This is a 11.22 percent decrease over losses of $(0.

BenzingaMay 3 05:12

Biomea Fusion 1Q Loss/Shr $1.09 >BMEA

Biomea Fusion 1Q Loss/Shr $1.09 >BMEA

Dow JonesMay 3 04:08

Press Release: Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights -- Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes

Dow JonesMay 3 04:05

DJT, BGFV and REAL Are Among After Hour Movers

Seeking AlphaApr 16 05:21

Biomea Fusion Price Target Maintained With a $70.00/Share by Oppenheimer

Biomea Fusion Price Target Maintained With a $70.00/Share by Oppenheimer

Dow JonesApr 3 22:11

Oppenheimer Maintains Outperform on Biomea Fusion, Maintains $70 Price Target

Oppenheimer analyst Hartaj Singh maintains Biomea Fusion with a Outperform and maintains $70 price target.

Analyst UpgradesApr 3 22:01

Biomea Fusion Drops as JPMorgan Downgrades on Data for Lead Asset

Seeking AlphaApr 3 01:18

Biomea Fusion Cut to Neutral From Overweight by JP Morgan

Biomea Fusion Cut to Neutral From Overweight by JP Morgan

Dow JonesApr 2 22:32

JP Morgan Downgrades Biomea Fusion to Neutral, Lowers Price Target to $14

JP Morgan analyst Gavin Scott downgrades Biomea Fusion from Overweight to Neutral and lowers the price target from $51 to $14.

Analyst UpgradesApr 2 22:22

Biomea Fusion Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 3.74% JP Morgan $51 → $14 Downgrades Overweight → Neutral 04/01/2024 270.51% HC Wainwright & Co

BenzingaApr 2 22:20

Analysts Have Conflicting Sentiments on These Healthcare Companies: Biomea Fusion (BMEA) and GoodRx Holdings (GDRX)

TipRanksApr 2 19:30